





STAY AHEAD OF ECZEMA WITH DUPIXENT

FDA-approved for ages 6 months and up with uncontrolled moderate-to-severe eczema (atopic dermatitis)



INDICATION

DUPIXENT is a prescription medicine used to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age.



KNOW WHAT TO LOOK FOR

Uncontrolled moderate-to-severe eczema (atopic dermatitis) can be difficult to manage. You might do everything right and still experience symptoms. But have you considered all your options? You may want to ask your doctor about making a change to your treatment.

WHEN SHOULD YOU TALK TO AN ECZEMA SPECIALIST? WHEN YOU OR YOUR CHILD:

- ► HAVE ECZEMA THAT KEEPS COMING BACK
- TAKE ORAL STEROIDS MORE THAN ONCE A YEAR
- TAKE IMMUNOSUPPRESSANTS MORE THAN ONCE A YEAR
- HIDE SKIN FROM OTHERS



Remember that good communication is the first step towards feeling better about your eczema. Scan code or <u>CLICK HERE</u> to download our Doctor Discussion Guide and get this conversation started with your specialist.

DID YOU KNOW?

► YOU CAN TAKE DUPIXENT WITH OR WITHOUT A TOPICAL CORTICOSTEROID (TCS)

IMPORTANT SAFETY INFORMATION: Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®. Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you: have eye problems; have a parasitic (helminth) infection; are scheduled to receive any vaccinations. You should not receive a "live vaccine" right before and during treatment with DUPIXENT.

Please see Important Safety Information throughout and click here for full <u>Prescribing Information</u> and <u>Patient Information</u>.

A DIFFERENCE INSIDE AND OUT

When topical prescriptions aren't enough, and your symptoms and flare-ups keep coming back, it might be time for a different kind of treatment like a biologic. And DUPIXENT is just that.


DUPIXENT is a breakthrough treatment for uncontrolled moderate-to-severe eczema.


DUPIXENT:

- ► IS A BIOLOGIC THAT HELPS BLOCK A KEY SOURCE OF INFLAMMATION INSIDE THE BODY THAT CAN CAUSE ECZEMA
- ► HELPS YOU STAY AHEAD OF SYMPTOMS FOR CLEARER SKIN AND LESS ITCH
- CONTINUOUSLY TREATS ECZEMA, EVEN BETWEEN FLARE-UPS
- ► IS NOT A STEROID OR IMMUNOSUPPRESSANT
- IS NOT TAKEN DAILY



IMPORTANT SAFETY INFORMATION: Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you (cont'd): are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/; are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.





TAKE CONTROL TAKE YOUR SHOT AGAINST ECZEMA

Many people with moderate-to-severe eczema have an overly active immune system that produces more inflammation under the skin than usual.

DUPIXENT helps block a key source of inflammation that may be causing your eczema symptoms. It works continuously on the inside to help heal your eczema on the outside. And, you don't take it every day—who wants to be reminded of their eczema on a daily basis?

DUPIXENT is a biologic—biologics are specialty medicines used to treat a variety of conditions, including chronic inflammatory diseases such as moderate-to-severe eczema. Biologics are processed in the body differently than oral or topical medications. To be effective and work in the body properly, most biologics are injectable medicines due to their size and the unique way they are made.



IMPORTANT SAFETY INFORMATION: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

MEANINGFUL RESULTS FROM CLINICAL TRIALS



HOW WERE THE TRIALS SET UP?

DUPIXENT was well studied in 6 clinical trials with 2,899 patients, ages 6 months through adult, to assess its safety profile, and to determine its efficacy in clearing skin and reducing itch.

Every age group studied had moderate and/or severe eczema that was uncontrolled with topical prescription medications.

DUPIXENT was first approved to treat adults with uncontrolled moderate-to-severe eczema by the FDA in 2017.



WHAT DID THE TRIALS MEASURE?

The trials measured skin clearance, itch reduction, and safety among people taking DUPIXENT compared to those who were not taking DUPIXENT. Each trial measured the results at 16 weeks. One trial measured the results at 16 and 52 weeks (1 year).



WHAT MEDICATIONS WERE USED?

Depending on the trial, participants received one of the following treatments:

- DUPIXENT
- Placebo (a treatment that appears to be real but contains no medicine)
- ► DUPIXENT with a topical corticosteroid (TCS)
- ▶ Placebo with TCS

DID YOU KNOW?

> YOU CAN TAKE DUPIXENT WITH OR WITHOUT
A TOPICAL CORTICOSTEROID (TCS)





~5 YEAR SAFETY **RESULTS IN ADULTS...**



LONG-TERM SAFETY RESULTS FOR ADULTS IN AN EXTENSION STUDY WERE CONSISTENT WITH THOSE SFFN IN THE ORIGINAL CLINICAL TRIALS

The most common side effects observed in clinical trials were: injection site reactions, eve and evelid inflammation. including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in the mouth or on the lips, and high count of a certain white blood cell (eosinophilia).

...AND IMPORTANT **CONSIDERATIONS**



STUDIED IN 15 CLINICAL TRIALS (6 IN ECZEMA, 9 IN 4 OTHER CONDITIONS)



#1 PRESCRIBED BIOLOGIC FOR ECZEMA BY DERMATOLOGISTS AND ALLERGISTS



NOT A STEROID OR IMMUNOSUPPRESSANT



NO INITIAL OR ROUTINE BLOOD WORK REQUIRED, PER PRESCRIBING INFORMATION



CAN BE USED WITH OR WITHOUT TOPICAL CORTICOSTEROIDS

Please see Important Safety Information throughout and click here for full Prescribing Information and Patient Information.



SHOW OFF CLEARER SKIN AND LESS ITCH

TRIAL RESULTS: DUPIXENT vs PLACEBO

TWO SEPARATE 16-WEEK CLINICAL TRIALS SHOWED:

~4X SAW CLEAR OR ALMOST CLEAR SKIN

37% vs 9% not taking DUPIXENT (placebo)

>3X HAD SIGNIFICANT ITCH REDUCTION

38% vs 11% not taking DUPIXENT

ALMOST HALF OF ADULTS SAW

≥75% CLEARER SKIN

48% vs 13% not taking DUPIXENT

MANY SAW

≥90% CLEARER SKIN

33% vs 7% not taking DUPIXENT

IMPORTANT SAFETY INFORMATION: Especially tell your healthcare provider if you are taking oral, topical or inhaled corticosteroid medicines or if you have atopic dermatitis and asthma and use an asthma medicine.

ADULTS (AGES 18+)

SHOW OFF WHAT'S POSSIBLE IN THE LONG RUN

TRIAL RESULTS: DUPIXENT + TOPICAL CORTICOSTEROIDS (TCS) vs TCS ONLY

LONG-TERM RESULTS FROM A CLINICAL TRIAL THAT STUDIED DUPIXENT FOR 52 WEEKS SHOWED:

CLEAR OR ALMOST CLEAR SKIN AT 16 WEEKS

39% taking DUPIXENT + TCS vs 12% using TCS only

LONG-LASTING CLEARER SKIN AT 16 AND 52 WEEKS

22% taking DUPIXENT + TCS vs 7% using TCS only

FAST ITCH RELIEF AS SOON AS 2 WEEKS

18% taking DUPIXENT + TCS vs 8% using TCS only

SIGNIFICANT ITCH REDUCTION AT 16 WEEKS

59% taking DUPIXENT + TCS vs 20% using TCS only

ITCH RELIEF THAT LASTS AT 52 WEEKS

51% taking DUPIXENT + TCS vs 13% using TCS only

IMPORTANT SAFETY INFORMATION: Do not change or stop your corticosteroid medicine or other asthma medicine without talking to your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.

Please see Important Safety Information throughout and click here for full <u>Prescribing Information</u> and <u>Patient Information</u>.





STAY AHEAD WITH CLEARER SKIN AND LESS ITCH

TRIAL RESULTS: DUPIXENT vs PLACEBO

TEENS TAKING PART IN A 16-WEEK CLINICAL TRIAL IN WHICH:

12X SAW CLEAR OR ALMOST CLEAR SKIN

24% vs 2% not taking DUPIXENT (placebo)

~7X EXPERIENCED ITCH RELIEF

37% vs 5% not taking DUPIXENT

IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including: Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue, or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area.

PROVEN RESULTS AND DEMONSTRATED SAFETY PROFILE IN TEENS

TRIAL RESULTS CONTINUED: DUPIXENT vs PLACEBO

TEENS TOOK PART IN A 16-WEEK CLINICAL TRIAL IN WHICH:

NEARLY HALF OF TEENS SAW

≥75% CLEARER SKIN

42% vs 8% in those not taking DUPIXENT

SOME EVEN SAW

≥90% CLEARER SKIN

23% vs 2% not taking DUPIXENT

YOU CAN TAKE DUPIXENT WITH OR WITHOUT A TOPICAL CORTICOSTEROID (TCS)

SAFETY RESULTS:

Long-term safety results for teens continuing on DUPIXENT in the pediatric extension study through 1 year were consistent with the adult clinical trials.

IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including (cont'd): Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision.





RESULTS THEY CAN FEEL RESULTS THEY CAN SHOW OFF

Caring for your child with uncontrolled moderate-to-severe eczema can be a struggle—especially when you're constantly trying to avoid triggers.

TRIAL RESULTS: DUPIXENT + TCS vs TCS ONLY

CHILDREN TAKING PART IN A 16-WEEK CLINICAL TRIAL IN WHICH:

>2X SAW CLEAR OR ALMOST CLEAR SKIN

30% on 300 mg every 4 weeks + TCS vs 13% on TCS only 39% on 200 mg every 2 weeks + TCS vs 10% on TCS only

~4.5X HAD LESS ITCH

54% on 300 mg every 4 weeks + TCS vs 12% on TCS only 61% on 200 mg every 2 weeks + TCS vs 13% on TCS only

YOUR HEALTHCARE PROVIDER WILL TELL YOU HOW MUCH DUPIXENT TO INJECT AND HOW OFTEN

IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including (cont'd): Eye problems. Your healthcare provider may send you to an ophthalmologist for an eye exam if needed.

PROVEN RESULTS AND DEMONSTRATED SAFETY PROFILE IN CHILDREN

TRIAL RESULTS CONTINUED: DUPIXENT + TCS vs TCS ONLY

CHILDREN TOOK PART IN A 16-WEEK CLINICAL TRIAL IN WHICH:

MORE THAN HALF OF CHILDREN SAW

≥75% CLEARER SKIN

75% on 300 mg every 4 weeks + TCS vs 28% on TCS only 75% on 200 mg every 2 weeks + TCS vs 26% on TCS only

YOUR HEALTHCARE PROVIDER WILL TELL YOU HOW MUCH DUPIXENT TO INJECT AND HOW OFTEN

➤ YOU CAN TAKE DUPIXENT WITH OR WITHOUT A TOPICAL CORTICOSTEROID (TCS)

SAFETY RESULTS:

Long-term safety results for children continuing on DUPIXENT with or without TCS in the pediatric extension study through 1 year were consistent with the adult clinical trials.

IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including (cont'd): Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms.





HEALING FROM WITHIN FOR YOUR LITTLE ONE

DUPIXENT is the only FDA-approved biologic for treating uncontrolled moderate-to-severe eczema in children as young as 6 months.

TRIAL RESULTS: DUPIXENT + TCS vs TCS ONLY

YOUNG CHILDREN TAKING PART IN A 16-WEEK CLINICAL TRIAL IN WHICH:

7X SAW CLEAR OR ALMOST CLEAR SKIN

28% on DUPIXENT + TCS vs 4% on TCS only

\sim 5X had less itch

48% on DUPIXENT + TCS vs 9% on TCS only

HALF OF YOUNG CHILDREN SAW

≥75% CLEARER SKIN

53% on DUPIXENT + TCS vs 11% on TCS only

➤ YOU CAN TAKE DUPIXENT WITH OR WITHOUT A TOPICAL CORTICOSTEROID (TCS)

SAFETY RESULTS:

Long-term safety results in young children continuing on DUPIXENT with or without TCS in the pediatric extension study through 1 year were consistent with the adult clinical trials. In addition, hand-foot-and-mouth disease and warts were reported. In these reported cases, patients continued treatment with DUPIXENT.

IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including (cont'd): Joint aches and pain. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.



HELPS HEAL THE LOOK AND FEEL OF SKIN

Eczema can affect anyone, regardless of age, ethnicity, or gender, and it can appear differently on different skin types. In some cases, eczema rashes may look red, gray, brown, or purple. DUPIXENT has shown generally consistent efficacy regardless of race/ethnicity in adult studies.



Actual 4-year-old patient in the clinical trial.† Individual results may vary.



Actual adult patient.



Actual 6-year-old patient in the clinical trial.† Individual results may vary.

IMPORTANT SAFETY INFORMATION: The most common side effects in patients with eczema include injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).

Please see Important Safety Information throughout and click here for full <u>Prescribing Information</u> and <u>Patient Information</u>.

<mark>26</mark> 27

^{*}This adult patient was an actual patient treated with DUPIXENT. Not clinical trial patient. Scoring was designated by the treating physician. Because this was a real-world patient, other factors may have influenced their treatment results. Individual results may vary.

[†]All patients were prescribed low or medium-potency topical corticosteroids (TCS) based on the clinical trial program.



DOSING FOR DUPIXENT® (dupilumab):

		BODY WEIGHT	INITIAL LOADING DOSE	SUBSEQUENT DOSAGE	
	ADULTS 18+	Any weight	600 mg (two 300-mg injections)	300 mg; every 2 weeks	
	CHILDREN & TEENS 6 TO 17 YEARS OF AGE	132 lb or more	600 mg (two 300-mg injections)	300 mg; every 2 weeks	
		66 lb to under 132 lb 400 mg (two 200-mg injection		200 mg; every 2 weeks	
		33 lb to under 66 lb	600 mg (two 300-mg injections)	300 mg; every 4 weeks	
		BODY WEIGHT	INITIAL* AND SUBSEQUEN	NT DOSAGE	
	YOUNG CHILDREN 6 Months to 5 years of age	33 lb to under 66 lb	300 mg; every 4 weeks		
		11 lb to under 33 lb	200 mg; every 4 weeks		

DUPIXENT is available as a pre-filled pen or pre-filled syringe.

Your doctor will tell you how much DUPIXENT to inject and how often to inject it, following proper training. DUPIXENT is an injection given under the skin (subcutaneous injection). Please rotate the injection site every time you administer DUPIXENT.



Pre-filled pen: available in 200 mg and 300 mg doses for patients aged 2+ years



SCAN CODE OR CLICK HERE TO WATCH THE SUPPLEMENTAL TRAINING VIDEOS ON HOW TO ADMINISTER DUPIXENT



Pre-filled syringe: available in 200 mg and 300 mg doses for patients aged 6+ months

*No loading dose recommended for young children.

DUPIXENT can be given by a doctor in the office or a caregiver at home:

- in children 6 months to less than 12 years, DUPIXENT should be given by a caregiver
- in teens 12-17 years, DUPIXENT should be given by or supervised by an adult

YOUR HEALTHCARE PROVIDER WILL DECIDE IF YOU OR YOUR CAREGIVER CAN INJECT DUPIXENT.



IMPORTANT SAFETY INFORMATION: Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Important Safety Information throughout and click here for full <u>Prescribing Information</u> and <u>Patient Information</u>.

DUPIXENT AND YOUA PERSONALIZED DOCTOR DISCUSSION GUIDE



Whether you're just beginning your treatment journey or looking for another way to treat your uncontrolled moderate-to-severe eczema, the following checklist is for both patients and caregivers. Think of this guide as the start of a conversation you can continue with your eczema specialist to help determine if DUPIXENT may be right for you or your loved one. Choose all that apply.

Please see Important Safety Information throughout and click here for full Prescribing Information and Patient Information.

Are you a patient or a caregiver?				How often do these symptoms occur?			
Patient	Caregive	r		ITCHING			
				Never	Rarely	Occasiona	lly Frequently
_	_	ne's treatment goals?		INFLAMED, DISCOLORED SKIN			
☐ Clearer skin ☐ Itch relief				☐ Never	Rarely	Occasiona	lly
	e you or your lo severe eczema?			THICKENED, HARDENED PATCHES OF SKIN			
0-2 years	2-5 years		☐ 10+ years	☐ Never	Rarely	Occasiona	Ily Frequently
What treatments have been prescribed or used for your or your loved one's eczema?				How often do flare-ups occur			
				☐ Every few months ☐ Monthly ☐ Weekly ☐ Daily			
☐ Topical ste	roids 🔲 Bio	ologics	None				
☐ Phototherapy ☐ Over-the-counter products				and for how long?			
Oral steroids Other				☐ 1-5 days ☐ 5-10 days ☐ 10-15 days ☐ 15+ day			
Describe your or your loved one's eczema symptoms.				Where are your or your loved one's eczema symptoms?			
RASH SEVERI	ITY			☐ Neck	Chest	☐ Stomach	☐ Front of Knees
None	☐ Mild	■ Moderate	Severe	☐ Face	☐ Elbows	Feet	☐ Back of Knees
ITCH INTENS	ITY			Hands	Ankles	☐ Scalp	Other
None	Mild	☐ Moderate	Severe	Describe any additional impact living with eczema has had on you or your loved one.			
IN ADODTANIT	CAFETVINIFO	DIATION II DIID	IVENT II				
		RMATION: Use DUP care provider. It's an i	,				
under the skin	ı (subcutaneous	injection). Your healtl giver can inject DUPIX	hcare provider				

30

Now that you've finished, just snap a photo to share with your eczema specialist at your next appointment




DUPIXENT MYWQY)

WITH YOU EVERY STEP OF THE WAY

Once you've been prescribed DUPIXENT, the *DUPIXENT MyWay®* patient support program is here to help answer questions you may have about DUPIXENT. Keep in mind your doctor is still the best resource for you if you have any questions about your eczema or your treatment program.

To enroll in *DUPIXENT MyWay*® and access helpful resources, call 1-844-DUPIXENT (1-844-387-4936) and select Option 1.



YOU'RE NOT ALONE

It's important to know that *DUPIXENT MyWay*® helps adults and children 6 months and up who are on or about to start DUPIXENT.



Once enrolled in the program, and while your insurance benefits are being confirmed for DUPIXENT, you will receive a Welcome Call from your Case Manager, who will explain the support available from DUPIXENT MyWay. In addition, your Case Manager can offer education and support to help you start and stay on track with your treatment.



Your DUPIXENT MyWay Case Manager can answer questions about DUPIXENT, arrange supplemental injection training, and help you start and stay on track.



With the DUPIXENT MyWay Patient App, people just like you can get access to tools to help you start and stay on track with your treatment. Contact your Case Manager for an invitation with directions on how to get the app.



The DUPIXENT MyWay Mentor Program gives you the opportunity to speak with other DUPIXENT patients and caregivers to hear their experiences.



SCAN CODE OR <u>CLICK HERE</u>
TO LEARN ABOUT ADDITIONAL
DUPIXENT MYWAY RESOURCES.

IMPORTANT SAFETY INFORMATION: Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it's recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see Important Safety Information throughout and click here for full <u>Prescribing Information</u> and <u>Patient Information</u>.



DUPIXENT MYWQY)

NEED HELP PAYING?

The DUPIXENT MyWay Copay Card Program may help reduce the out-of-pocket cost of DUPIXENT. Eligible patients may pay as little as \$0* per fill for each DUPIXENT prescription (maximum of \$13,000 per patient per calendar year).*

AS LITTLE AS \$0* COPAY MAY BE AVAILABLE IF YOU:

- ► Have commercial insurance
- Have a DUPIXENT prescription for an FDA-approved condition
- Reside in the 50 United States, the District of Columbia, Puerto Rico, Guam, or the USVI
- Are a patient or caregiver 18 years or older

*Approval is not guaranteed. Program has an annual maximum of \$13,000. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.

OTHER OPTIONS FOR SUPPORT

Through the Patient Assistance Program, eligible patients who are uninsured or rendered uninsured by their insurance provider could receive DUPIXENT free of charge if they qualify.

Those who may qualify must be at least 18 years of age or older, a resident of the 50 United States, the District of Columbia, Puerto Rico, Guam, or the USVI, and demonstrate a financial need.

Call DUPIXENT MyWay® at 1-844-387-4936 for full program information and eligibility criteria.





HELP HEAL YOUR SKIN FROM WITHIN



IMPORTANT SAFETY INFORMATION: Do not use if you are allergic to dupilumab or to any of the ingredients in **DUPIXENT®**.

Please see Important Safety Information throughout and click here for full <u>Prescribing Information</u> and <u>Patient Information</u>.

sanofi REGENERON®

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved. DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology. US.DUP.23.09.0173 02/24